MS4A1 and B-cell non-Hodgkin lymphoma: Furthermore, Fc‐silenced Brainshuttle‐CD20 mAbs display potent direct B cell death induction capacity, demonstrated by a reduction of human B cell lymphoma cells, as well as primary human B cells in WBA, tonsil‐derived cell cultures, and human CSF‐cultured PBMCs.